Vinnova, together with Swelife and Medtech4health, have jointly called for new innovative projects within life science and medical technology. The goal is to promote sustainability and innovation, generating value-creating healthcare and increasing growth in the Swedish life science sector. A consortium, led by TIRmed Pharma, have successfully been approved a grant of up to 1.5 MSEK in this programme.
TIRmed Pharma, together with Research Institutes of Sweden (RISE) and supported by the patient association Atopikerna (a part of Astma- och Allergiförbundet), have developed a project to drive the development of TIRmed Pharma’s new topical treatment for Atopic Dermatitis; TIR-C.
The consortium’s primary objective is to bring TIR-C to pre-clinical trials; a key milestone on the greater path towards bringing it to market. Three main outcomes of the project will support this: Statistically relevant indication of efficacy in dogs, established bioanalytical methods and key insights from patients suffering from Atopic Dermatitis. Combined, these potential results will set a strong foundation for TIR-C's future.
VinnovaVinnova is Sweden’s innovation agency. They help to build Sweden's innovation capacity, contributing to sustainable growth. Their vision is that Sweden is an innovative force in a sustainable world.
SwelifeSwelife is a strategic innovation programme, funded by the Swedish Government via the Swedish innovation agency, Vinnova, and by the programme’s partners. Swelife support collaboration within academia, industry and healthcare, with the goal to strengthen Life Science in Sweden and to improve public health.
Medtech4health Medtech4Health strive to increase the number and quality of new innovative products and services within medtech. In collaboration with patients, healthcare, academia and business, they will increase value for people affected by disease in their everyday lives. Medtech4Health is funded by the Swedish government through the innovation authority Vinnova and by the programme’s partners.